Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
Jann N. Sarkaria(Mayo Clinic in Arizona), C. David James(Mayo Clinic in Arizona), Wenting Wu(East China Normal University), Evanthia Galanis(Mayo Clinic in Arizona), Brett L. Carlson(University of California, San Francisco), Caterina Giannini(Mayo Clinic), Patrick T. Grogan(Moffitt Cancer Center), Mark A. Schroeder(MACOM (United States)), Lin Yang(Mayo Clinic), Gaspar J. Kitange(Hormel (United States)), Eduard B. Dinca(Mayo Clinic)
Cited by 203
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells
|BMC Medicine|2008|948
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
|Journal of Clinical Oncology|2005|695